Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
BIOVIE INC. (BIVI) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/23/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
03/13/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "FIRST AMENDMENT TO BYLAWS OF BIOVIE INC. Adopted on March 12, 2023 The Bylaws of BioVie Inc. are amended as follows: Article III, Section 1 is amended in its entirety to read as follows: Section 1. Number and Term. The number of directors of the Corporation shall be fixed as the Board of Directors may from time-to-time designate, provided that the number of members of the Board shall not be less than three nor more than eleven . The number of authorized directors may be changed solely by action of the Board of Directors. No decrease in the number of directors shall have the effect of shortening the term of any incumbent director. Article III, Section 8, third paragraph is deleted, and the following two paragraphs are substituted: Regular meetings of the Board of Directors may be scheduled ..."
03/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/23/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "50 West Liberty Street, Suite 1000, Reno, Nevada 89501-1950 Telephone: 775.323.1980 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169 Telephone: 702.387.6073 BioVie Inc. 680 West Nye Lane, Suite201 Carson City, Nevada 489703"
12/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "50 West Liberty Street, Suite 1000, Reno, Nevada 89501-1950 Telephone: 775.323.1980 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169 Telephone: 702.387.6073 BioVie Inc. 680 West Nye Lane, Suite 201 Carson City, Nevada 489703"
12/07/2022 8-K Quarterly results
12/06/2022 8-K Quarterly results
12/05/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/04/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BioVie Issues Letter to Shareholders ● Positive preliminary data from investigator-sponsored Phase 2 Alzheimer’ s trial show high proportion of responders and level of cognitive improvements seen for NE3107 confirm NE3107’ s status as one of the most promising candidates in the Alzheimer’ s space ● Potentially pivotal Phase 3 trial for NE3107 in Alzheimer’ s has enrolled over half the targeted patients and is on track to readout mid-2023 ● Early and preliminary evidence in Phase 2 Parkinson’ s trial for NE3107 may suggest findings consistent with that previously seen in non-human primates and should readout before year-end 2022 ● Three significant data readouts expected over the next 12 months Carson City, NV, October 4, 2022 – BioVie Inc., a clinical-stage company..."
09/07/2022 8-K/A Investor presentation
Docs: "BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’ s Disease BioVie Provides Updates on Other Clinical Programs"
09/07/2022 8-K Investor presentation
Docs: "BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’ s Disease BioVie Provides Updates on Other Clinical Programs"
08/31/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement",
"50 West Liberty Street, Suite 1000, Reno, Nevada 89501-1950 Telephone: 775.323.1980 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169 Telephone: 702.387.6073 BioVie Inc. 680 West Nye Lane, Suite201 Carson City, Nevada 489703"
07/18/2022 8-K/A Quarterly results
07/15/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
12/01/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Loan Agreement",
"Loan Agreement",
"ASSIGNMENT",
"BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. Reno, NV, December 1, 2021 – BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, entered into a debt facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. providing up to $25 million with the initial $15 million funded at the close on November 30, 2021. “We are pleased to partner with the Avenue Venture Funds as we prepare for a catalyst-rich 2022, which includes anticipated top-line data from both our Phase 2b trial of BIV201 in refractory ascites and our Phase 3 trial of NE3107 in Alzh..."
10/14/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/11/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "UNDERWRITING AGREEMENT",
"BioVie Inc.",
"SANTA MONICA, Calif., August 8, 2021",
"BioVie Inc. Announces Closing of Public Offering of Common Stock SANTA MONICA, Calif., August 11, 2021 – BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced the closing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering price of $8.00 per share, for gross proceeds of $20,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45 day option to purchase up to an additional 375,000 shares of common stock to cover over-allotments at the offering price, less the underwriting discount. ThinkEquity, a division of Fordham..."
08/05/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer's Disease SANTA MONICA, Calif., August 5, 2021 -- BioVie Inc. , a clinical-stage company developing innovative drug candidates for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced that the Company has enrolled the first patient into the NM101 Phase III clinical study testing NE3107 for the treatment of Alzheimer's Disease ."
06/11/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
09/23/2020 8-K Quarterly results
06/22/2020 8-K Quarterly results
11/15/2019 8-K Quarterly results
10/08/2019 8-K Quarterly results
06/28/2019 8-K Quarterly results
06/28/2019 8-K Quarterly results
01/28/2019 8-K Quarterly results
12/31/2018 8-K Completion of Acquisition or Disposition of Assets
11/29/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "BioVie’ s New Drug Candidate BIV201 Receives FDA Orphan Drug Designation for the Treatment of Hepatorenal Syndrome BioVie Inc. , a clinical-stage company developing innovative drug therapies for liver disease, announced today that the US Food and Drug Administration has granted an Orphan Drug designation to BioVie for terlipressin for the treatment of hepatorenal syndrome . BIV201 is a new drug candidate currently being tested in a mid-stage clinical study in patients with refractory ascites due to advanced liver cirrhosis. The Company previously secured an Orphan Drug designation for terlipressin for treating ascites, and is exploring additional Orphan designation opportunities. “An estimated 12,000 to 33,000 Americans develop HRS each year,” said BioVie CEO Terren Peizer. “Our novel drug..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy